Whitehawk Therapeutics (WHWK) Operating Margin (2018 - 2025)
Whitehawk Therapeutics (WHWK) has disclosed Operating Margin for 7 consecutive years, with 212.99% as the latest value for Q1 2025.
- On a quarterly basis, Operating Margin rose 15152.0% to 212.99% in Q1 2025 year-over-year; TTM through Sep 2025 was 754.05%, a 48989.0% decrease, with the full-year FY2024 number at 259.62%, up 3574.0% from a year prior.
- Operating Margin was 212.99% for Q1 2025 at Whitehawk Therapeutics, up from 261.76% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 1707.05% in Q2 2021 to a low of 3405.83% in Q1 2021.
- A 5-year average of 378.42% and a median of 291.39% in 2022 define the central range for Operating Margin.
- Biggest YoY gain for Operating Margin was 280705bps in 2022; the steepest drop was -224124bps in 2022.
- Whitehawk Therapeutics' Operating Margin stood at 113.89% in 2021, then plummeted by -160bps to 296.0% in 2022, then grew by 5bps to 280.02% in 2023, then increased by 7bps to 261.76% in 2024, then grew by 19bps to 212.99% in 2025.
- Per Business Quant, the three most recent readings for WHWK's Operating Margin are 212.99% (Q1 2025), 261.76% (Q4 2024), and 185.98% (Q3 2024).